Contec Medical Systems Co.,Ltd (SHE:300869)
China · Delayed Price · Currency is CNY 9.47
-0.33 (-3.37%)
Nov 13, 2026, 3:04 PM CST
SHE:300869 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 473.75 | 464 | 476.07 | 742.65 | 708.68 | 904.84 |
Other Revenue | 4 | 4 | 3.73 | 4.25 | 3.43 | 3.87 |
| 477.75 | 468 | 479.81 | 746.9 | 712.11 | 908.71 | |
Revenue Growth | -2.48% | -2.46% | -35.76% | 4.88% | -21.63% | -35.15% |
Cost of Revenue | 306.68 | 272.33 | 356.53 | 359.82 | 382.12 | 476.88 |
Gross Profit | 171.07 | 195.67 | 123.27 | 387.08 | 330 | 431.83 |
Selling, General & Admin | 141.97 | 148.4 | 125.28 | 155.58 | 122.4 | 95.53 |
Research & Development | 88.69 | 91.66 | 105.16 | 110.6 | 93.25 | 66.06 |
Other Operating Expenses | 11.13 | 3.06 | 3.42 | -14.44 | 3.78 | -2.84 |
Operating Expenses | 240.16 | 241.77 | 235.3 | 250.71 | 221.45 | 159.13 |
Operating Income | -69.09 | -46.1 | -112.03 | 136.38 | 108.55 | 272.7 |
Interest Expense | -2.68 | -37.43 | -35.3 | -45.1 | -19.08 | -2.86 |
Interest & Investment Income | 31.76 | 66.53 | 71.06 | 92.65 | 92.23 | 68.64 |
Currency Exchange Gain (Loss) | -15.33 | -15.33 | 6.66 | -2.95 | -13.31 | 60.92 |
Other Non Operating Income (Expenses) | -34.58 | -1.1 | -1.96 | -2.23 | -1.5 | -0.94 |
EBT Excluding Unusual Items | -89.92 | -33.42 | -71.58 | 178.75 | 166.89 | 398.45 |
Gain (Loss) on Sale of Investments | 0.73 | 1.77 | 1.59 | 2.02 | 46.64 | - |
Gain (Loss) on Sale of Assets | -0.01 | 0 | 0.17 | -0.07 | -0.26 | -0.04 |
Asset Writedown | -13.54 | -0.17 | -0.25 | - | -0.01 | -0.02 |
Other Unusual Items | 6.6 | 4.93 | -3.81 | 5.42 | 6.14 | 9.61 |
Pretax Income | -96.13 | -26.89 | -73.89 | 186.13 | 219.39 | 407.99 |
Income Tax Expense | -5.02 | -2.46 | 4.02 | 20.36 | 23.19 | 55.64 |
Net Income | -91.11 | -24.42 | -77.9 | 165.77 | 196.2 | 352.35 |
Net Income to Common | -91.11 | -24.42 | -77.9 | 165.77 | 196.2 | 352.35 |
Net Income Growth | - | - | - | -15.51% | -44.32% | -42.56% |
Shares Outstanding (Basic) | 407 | 407 | 410 | 404 | 400 | 402 |
Shares Outstanding (Diluted) | 407 | 407 | 410 | 414 | 409 | 402 |
Shares Change | -0.56% | -0.72% | -1.06% | 1.39% | 1.73% | 7.43% |
EPS (Basic) | -0.22 | -0.06 | -0.19 | 0.41 | 0.49 | 0.88 |
EPS (Diluted) | -0.22 | -0.06 | -0.19 | 0.40 | 0.48 | 0.88 |
EPS Growth | - | - | - | -16.67% | -45.26% | -46.53% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -13.18 | -27.19 | 7.88 | 150.28 | 22.21 | -101.66 |
Free Cash Flow Per Share | -0.03 | -0.07 | 0.02 | 0.36 | 0.05 | -0.25 |
Dividend Per Share | - | - | 0.250 | 0.300 | 0.125 | 0.300 |
Dividend Growth | - | - | -16.67% | 140.00% | -58.33% | 20.00% |
Gross Margin | 35.81% | 41.81% | 25.69% | 51.82% | 46.34% | 47.52% |
Operating Margin | -14.46% | -9.85% | -23.35% | 18.26% | 15.24% | 30.01% |
Profit Margin | -19.07% | -5.22% | -16.24% | 22.19% | 27.55% | 38.77% |
Free Cash Flow Margin | -2.76% | -5.81% | 1.64% | 20.12% | 3.12% | -11.19% |
EBITDA | -43.83 | -20.53 | -86.04 | 161.92 | 127.51 | 290.34 |
EBITDA Margin | -9.18% | -4.39% | -17.93% | 21.68% | 17.91% | 31.95% |
D&A For EBITDA | 25.26 | 25.57 | 25.99 | 25.54 | 18.96 | 17.64 |
EBIT | -69.09 | -46.1 | -112.03 | 136.38 | 108.55 | 272.7 |
EBIT Margin | -14.46% | -9.85% | -23.35% | 18.26% | 15.24% | 30.01% |
Effective Tax Rate | - | - | - | 10.94% | 10.57% | 13.64% |
Revenue as Reported | 477.75 | 468 | 479.81 | 746.9 | 712.11 | - |
Advertising Expenses | - | 38.18 | 7.76 | 8.32 | 3.8 | 6.21 |